Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum resistant ovarian cancer (PROC)

 PDF   18   05/2021

Clinical presentation by Cheng Chen, M.D.

Rating

Rate this resource